<DOC>
	<DOC>NCT01465230</DOC>
	<brief_summary>This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).</brief_summary>
	<brief_title>Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Previous induction treatment with bendamustine and rituximab 18 or more years of age chronic lymphocytic leukemia ECOG performance status less than or equal to 2 Absolute neutrophile count more than 1,000 Platelet count more than 70,000 Serious medical condition that would prevent treatment with lenalidomide Evidence of tumor lysis syndrome Any prior treatment with lenalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>